RKLB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient trader. RKLB is selling off hard (-5.67% today) on an event-driven negative (Neutron tank rupture / potential launch delay) while momentum indicators remain bearish (MACD histogram negative and expanding). Price is sitting right on key support (~81.5); if that level fails, the next downside area is ~76.9, making the immediate risk/reward unattractive without a confirmed bounce. With no Intellectia proprietary buy signals today and options flow leaning defensive intraday (put-heavy volume), the better call right now is HOLD/avoid initiating new long exposure at this moment.
Trend/momentum: Bearish short-term. MACD histogram is -1.701 and negatively expanding, signaling strengthening downside momentum. RSI(6) at ~38.8 is weak but not yet deeply oversold (no clear reversal signal). Moving averages are converging, consistent with a transition phase but currently not confirming a renewed uptrend. Key levels: Current price ~81 is essentially at S1 81.507 (critical near-term support). A clean break below support increases probability of a move toward S2 ~76.888. Overhead resistance is the pivot ~88.983, then R1 ~96.458. Near-term setup favors waiting for either (1) a bounce/reclaim back above ~89, or (2) a flush toward ~77 with stabilization—neither is confirmed today. Pattern-based forward view provided: Similar-candlestick stats imply only modest edge (50% chance of -1.91% next day; +1.74% next week), which doesn’t offset today’s event risk + bearish momentum.
Successful Electron mission (NEONSAT-1A) and continued demonstrated demand for small-sat launches.
Large SDA award (~$805M) previously cited by multiple analysts supports backlog/credibility in national security space.
Street tone into 2026 has been constructive (multiple upgrades/raised targets in January), implying longer-term institutional interest.
Trading trends show hedge funds buying aggressively (reported +9284.72% QoQ buying amount), supportive for medium-term sentiment.
is the core near-term overhang.
Latest reported quarter: 2025/Q3. Revenue rose to $155.08M (+47.97% YoY), showing strong top-line growth. Gross margin improved to 36.96% (+38.38% YoY), a meaningful operational positive. However, profitability metrics weakened: net income was -$18.257M (more negative YoY as reported) and EPS was -$0.03 (down -70% YoY). Overall: strong growth and margin improvement, but losses and EPS deterioration show the business is still absorbing significant program costs (consistent with Neutron development spend).
Recent trend: Ratings and price targets have generally moved up into early 2026, reflecting improved industry outlook and major contract wins. Key actions include Morgan Stanley upgrade to Overweight with PT $105 (from $67) and BofA reiterating Buy while raising PT to $120 (from $60). Needham and Stifel also raised targets following the SDA award. TD Cowen kept Buy with $100 PT but flagged the Neutron tank rupture as a potential schedule-delay risk. Goldman raised PT to $69 but stays Neutral. Wall Street pros: (1) growing defense/space systems credibility and backlog (SDA award), (2) vertical integration and Neutron as a step-change catalyst, (3) strong revenue growth and margin progress. Wall Street cons: (1) Neutron schedule/technical risk and potential cascading manifest impacts, (2) prolonged program spend delaying profitability, (3) near-term headline sensitivity. Influential/political activity: No recent congress trading data available in the last 90 days; no politician/influential figure trades were provided. Intellectia Proprietary Trading Signals: No signal on given stock today.
